LABORATORY OF ENDOCRINOLOGY                                                                                                                      Russian version

 

Main Research Field

Diabetic Complications: Clinical and Translational Research

 

Research Subjects

  • Angiogenesis and inflammation in diabetes
  • Genetics of diabetic vascular complications
  • Glycemic variability and glucose trend prediction
  • Assessment of new antidiabetic drugs
  • Osteoporosis in diabetes  

Head of Laboratory

Prof. Vadim Klimontov, MD, PhD

Dr. V. Klimontov graduated from the Medical Faculty of the Novosibirsk Medical Institute in 1996. He took postgraduate training courses in Endocrinology and Diabetology in Research Center of Endocrinology (Moscow), Oxford Centre for Diabetes, Endocrinology and Metabolism (UK), and Erasmus University Medical Center in Rotterdam (the Netherlands). Dr. V. Klimontov also had a set of clinical trainings at University Hospital Salzburg (Austria). In 2008 he defended his thesis on the mechanisms of development and the makers of initial stages of chronic kidney disease in patients with type 1 diabetes.

His current scientific activity covers such areas as genetics, pathogenesis and the markers of the vascular diabetic complications, assessment of glucose variability and prediction of glucose trends, and novel antidiabetic modalities. As a Deputy Director for Science, Prof. V. Klimontov coordinates the scientific research in the Scientific Institute of Clinical and Experimental Lymphology. Dr. V. Klimontov is a member of European Association for the Study of Diabetes (EASD) and American Diabetes Association (ADA). His is author of more than 80 articles in peer-review journals. His research projects were supported by the grants from EASD, RF Presidential Council on grants, and Russian Science Foundation. In 2016 Dr. V. Klimontov was awarded the honorary title of Professor of the Russian Academy of Science.

Research Group

 

 

 

Dr. Elena Koroleva, MD, PhD

 

 

 

Dr. Dinara Bulumbaeva, MD

 

 

 

Dr. Olga Fazullina, MD

 

 

 

Dr. Anton Korbut, MD

 

 

 

Dr. Natalia Myakina, MD

 

 

 

Dr. Nadezda Tyan, MD

 

Staff

 

 

 

Marina Cherepanova

 

 

 

 

 

 

Selected Publications

2017

Korbut AI, Klimontov VV. Empagliflozin: a new strategy for nephroprotection in diabetes. Diabetes Mellitus 2017; 20 (1): 75-84.doi: 10.14341/DM8005

 

2016

1. Lingvay I, Manghi FP, García-Hernández P, Norwood P, Lehmann L, Tarp-Johansen MJ, Buse JB; DUAL V Investigators. Effect of insulin glargine up-titration vs insulin degludec/liraglutide on glycated hemoglobin levels in patients with uncontrolled type 2 diabetes: the DUAL V randomized clinical trial. JAMA. 2016;315(9):898-907. doi: 10.1001/jama.2016.1252.

2. Korbut AI, Klimontov VV. Incretin-based therapy: renal effects. Diabetes Mellitus. 2016;19(1):53-63. Russian. doi: 10.14341/DM7727.

3. Klimontov VV, Myakina NE, Tyan NV. Heart rate variability is associated with interstitial glucose fluctuations in type 2 diabetic women treated with insulin. SpringerPlus 2016;5:337. doi: 10.1186/s40064-016-1932-z.

4. Klimontov VV, Tyan NV, Orlov NB, Shevchenko AV. Serum levels of VEGF family angiogenic factors and VEGF-A gene polymorphism are associated with coronary artery disease in type 2 diabetic patients. Diabetes 2016; 65: A109.
5. Klimontov VV, Shevchenko AV, Tyan NV. Serum levels and genetic variants of inflammatory cytokines are associated with coronary artery disease in type 2 diabetic subjects. Diabetes 2016; 65: A113-114.
6. Klimontov VV, Tyan NV, Lykov AP, Bondarenko NA, Myakina NE. Lack of association between production of cytokines, NO, and MMP-9 by peripheral blood mononuclear cells and glycemic variability in type 2 diabetic patient. Diabetes 2016; 65: A436.

7. Ovsyannikova AK, Rymar OD, Shakhtshneider EV, Klimontov VV, Koroleva EA, Myakina NE, Voevoda MI. ABCC8-Related Maturity-onset diabetes of the young (MODY12): clinical features and treatment perspective. Diabetes Ther. 2016; 7(3): 591-600. doi: 10.1007/s13300-016-0192-9.

8. Klimontov VV, Tyan NV, Bulumbaeva DM, Orlov NB, Konenkov VI. Serum levels of angiogenic regulators in type 2 diabetic patients: the relationships with cardiovascular complications. Diabetologia. 2016; 59 (S1): S539.

9. Tyan NV, Klimontov VV, Shevchenko AV, Fazullina ON, Orlov NB, Konenkov VI. Polymorphisms in the gene promoters of IL4, IL6, IL10 and TNFA associated with serum levels of cytokines in type 2 diabetic subjects. Diabetologia. 2016; 59 (S1): S513.

10. Klimontov VV, Tyan NV, Fazullina ON, Myakina NE, Lykov AP, Konenkov VI. Clinical and metabolic factors associated with chronic low-grade inflammation in type 2 diabetic patients. Diabetes Mellitus. 2016; 19 (4): 295-302. Russian. doi: doi: 10.14341/DM7928.

11. Michurina S.V., Ischenko I.Ju., Klimontov V.V., Archipov S.A., Myakina N.E., Cherepanova M.A., Zavjalov E.L., Koncevaya G.V., Konenkov V.I. Linagliptin alleviates fatty liver disease in diabetic db/db mice. // World J. Diabetes. – 2016. – Vol. 7, N. 19. – P. 534-546. doi: 10.4239/wjd.v7.i19.534.

12. Klimontov VV, Fazullina ON, Lykov AP, Konenkov VI. The relationships between bone turnover markers and bone mineral density in postmenopausal type 2 diabetic women. Diabetes mellitus. 2016; 19 (5): 375-382. doi: 10.14341/DM8008


2015

1. Klimontov VV, Fazullina ON. The relationship of total body composition with bone mineral density in postmenopausal women with type 2 diabetes. Diabetes Mellitus 2015;18(1):65-69. doi: 10.14341/DM2015165-69.

2. Klimontov VV, Eremenko NV, Myakina NE, Fazullina ON. Cystatin C and collagen type IV in diagnostics of chronic kidney disease in type 2 diabetic patients. Diabetes Mellitus. 2015;18(1): 87-93. Russian. doi: 10.14341/DM2015187-93.

3. Klimontov VV, Bgatova NP, Gavrilova JuS, Ischenko IJu, Myakina NE, Michurina SV, Zavjalov EL. Linagliptin allieviate renal injury in a model of type 2 diabetic nephropathy. Diabetes. 2015;64(S.1):A144.

4. Myakina NE, Klimontov VV, Safarov DM. Glucose fluctuations аnd heart rate variability in tуре 2 diabetic patients: The Results of simultaneous glucose and ECG monitoring. Diabetes 2015;64(S.1):A166.

5. Klimontov VV, Myakina NE, Tyan NV, Romanov VV. Elevated levels of circulating macrophage-related inflammatory cytokines in tуре 2 diabetic patients with chronic kidney disease. Diabetes. 2015;64(S.1):A614-A615.

6. Konenkov VI, Klimontov VV, Myakina NE, Tian NV, Fazullina ON, Romanov VV. Increased serum concentrations of inflammatory cytokines in type 2 diabetic patients with chronic kidney disease. Ter Arkh. 2015;87(6):45-49. Russian. doi: 10.17116/terarkh201587645-49. WOS:000358823600008 

7. Myakina NE, Klimontov VV. Nocturnal hypoglycemia can be predicted by retrospective analysis of glucose variability in elderly type 2 diabetic patients treated by insulin. Diabetologia. 2015;58(S.1):S416.

8. Klimontov VV, Myakina NE, Tyan NV. Systemic inflammation and glucose variability in type 2 diabetic patients with and without chronic kidney disease. Diabetologia. 2015;58(S.1):S544.

9. Klimontov VV, Myakina NE. The relationships between glucose variability and renal function in type 2 diabetes patients on basal-bolus insulin therapy. Diabetes Mellitus. 2015;18(4):66-71. doi: 10.14341/DM7181.

2014

1. Konenkov VI, Klimontov VV. Gene and cell-based technologies for the treatment of diabetic foot syndrome. Diabetes Mellitus 2014;17(1):63-69. doi: 10.14341/DM2014163-69.

2. Klimontov VV, Tsiberkin AI, Fazullina ON, Prudnikova MA, Tyan NV, Konenkov VI. Hypoglycemia in type 2 diabetes patients treated with insulin: the advantages of continuous glucose monitoring. Diabetes Mellitus. 2014;17(1):75-80. Russian. doi: 10.14341/DM2014175-80.

3. Konenkov VI, Klimontov VV, Kuznetsova IV. Impaired angiogenesis and lymphangiogenesis in diabetes mellitus. Arkh Patol. 2014;76(2):55-59. Review.

 4. Klimontov VV, Myakina NE. Glycaemic variability in diabetes: a tool for assessing the quality of glycaemic control and the risk of complications. Diabetes Mellitus. 2014;17(2):18-24. doi: 10.14341/DM20142.

5. Klimontov VV, Myakina NE. Insulin glargine: Pharmacokinetic and pharmacodynamic basis of clinical effect. Diabetes Mellitus 2014;17(4):99-107. doi: 10.14341/DM2014499-107.

2013

1. Konenkov VI, Klimontov VV, Michurina SV, Prudnikova MA, Ishenko IJ. Melatonin and diabetes: from pathophysiology to the treatment perspectives. Diabetes Mellitus. 2013;16(2):11-16. doi: 10.14341/2072-0351-3751.

2. Klimontov VV, Tsiberkin AI, Fazullina ON, Prudnikova MA, Tyan NV, Konenkov VI. Glucose variability and hypoglycaemic excursions in elderly type 2 diabetic patients treated with insulinDiabetologia. 2013;56(S.1):S239.

3. Konenkov VI, Klimontov VV, Chernykh VV, Tjan NV. Anti-VEGF agents in the treatment of diabetic macular edema. Diabetes Mellitus. 2013;16(4):78-84. Russian. doi: 10.14341/DM2013478-84. 

2012

1.Konenkov VI, Shevchenko AV, Prokof'ev VF, Klimontov VV, Korolev MA, Fazullina ON, Lapsina SA, Koroleva EA. Associations of vascular endothelial growth factor (VEGF) gene and cytokine (IL-1B, IL-4, IL-6, IL-10, TNFA) genes combinations with type 2 diabetes mellitus in women. Diabetes Mellitus. 2012;15(3):4-10. doi: org/10.14341/2072-0351-6079. web:

2. Konenkov VI, Klimontov VV. Vasculogenesis and angiogenesis in diabetes mellitus: novel pathogenetic concepts for treatment of vascular complications. Diabetes Mellitus. 2012; 15(4): 17-27. doi: 10.14341/2072-0351-5533

 

Selected Conference Presentations     

2015

1. Klimontov VV, Bgatova NP, Gavrilova JuS, Ischenko IJu, Myakina NE, Michurina SV, Zavjalov EL. Linagliptin allieviate renal injury in a model of type 2 diabetic nephropathy. 75th Scientific Session of American Diabetes Association. Boston, June 5-9, 2015. 563-P

2. Myakina NE, Klimontov VV, Safarov DM. Glucose fluctuations аnd heart rate variability in tуре 2 diabetic patients: The Results of simultaneous glucose and ECG monitoring. 75th Scientific Session of American Diabetes Association. Boston, June 5-9, 2015. 653-P

3. Myakina NE, Klimontov VV. Nocturnal hypoglycemia can be predicted by retrospective analysis of glucose variability in elderly type 2 diabetic patients treated by insulin. 51th Annual Meeting of the European Association for the Study of Diabetes. Stockholm, 2015. PP 864.

4. Klimontov VV, Myakina NE, Tyan NV. Systemic inflammation and glucose variability in type 2 diabetic patients with and without chronic kidney disease. 51th Annual Meeting of the European Association for the Study of Diabetes. Stockholm, 2015. PP 1133.

2014

1. Tabakov K, Myakina N. Glucose trend prediction in diabetic patients using Random Forests algorithm for analysis of CGM data. 50th Annual Meeting of the European Association for the Study of Diabetes. Vienna, 2014. PP 996.

2013

1. Klimontov VV, Tsiberkin AI, Fazullina ON, Prudnikova MA, Tyan NV, Konenkov VI. Glucose variability and hypoglycaemic excursions in elderly type 2 diabetic patients treated with insulin49th Annual Meeting of the European Association for the Study of Diabetes. Barcelona, 2013. PP 590.

2. Klimontov VV, Bondar IA, Parfentjeva EM, Romanov VV, Bgatova NP. Urinary excretion of site-specific tubular markers in patients with type 1 diabetes. World Diabetes Congress. Melbourne, 2013. 

 

Clinical Trials

NN9068-3952 A trial comparing the efficacy and safety of insulin degludec/liraglutide versus insulin glargine in subjects with type 2 diabetes mellitus.

M11-352 A Randomized, Multicountry, Multicenter, Double-Blind, Parallel, Placebo-Controlled Study of the Effects of Atrasentan on Renal Outcomes in Subjects with Type 2 Diabetes and Nephropathy.

GEMIGL07185 Phase 3 Study to Compare the Efficacy and Safety of Gemigliptin and Vildagliptin as Add-on Therapy to Metformin in People With Type 2 Diabetes Inadequately Controlled With Metformin.

OBS13780 Multinational, Prospective, Observational Study to Assess the Unmet Medical Needs associated with Basal Insulin Use in Patients with Type 2 Diabetes Newly or Recently Initiated with Basal Insulin Treatment.

NN9068-4228 A 104 week clinical trial comparing long term glycaemic control of insulin degludec/liraglutide (IDegLira) versus insulin glargine therapy in subjects with type 2 diabetes mellitus.

BAY 94-8862 (finerenone) / 16244 A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven Phase III study to investigate the efficacy and safety of finerenone, in addition to standard of care, on the progression of kidney disease in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease.

BAY 94-8862 (finerenone) / 17530 A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven Phase III study to investigate the efficacy and safety of finerenone on the reduction of cardiovascular morbidity and mortality in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease in addition to standard of care.

NN1218-4131 Efficacy and Safety of Faster-acting Insulin Aspart compared to NovoRapid® both in combination with Insulin Degludec in Adults with Type 1 Diabetes.

 

Contacts

Arbuzov Street 6, 630117, Novosibirsk, Russia

Tel. +7-383-335-96-33

E-mail: klimontov@mail.ru